November 21, 2023

Characterizing the ILD (interstitial lung disease) Care Continuum Using Real World Evidence

Study Updated 03/28/2024

Study Design: Retrospective Observational
PCORnet Infrastructure: Collaboration, CDM, Engagement
Principal Investigator: Aparna Swaminathan
Site Name: Duke Clinical Research Institute
PCORnet® Network Partner: Coordinating Center
Funder: Genentech
Funding Date: 2021
Study Duration: 2022 – 2024
Participating Clinical Research Networks: GPC, INSIGHT, PaTH, STAR
Therapeutic Area: Pulmonary
Condition: Idiopathic Pulmonary Fibrosis (IPF)
Population: 18 Years and older (Adult,  Older Adult )
Status: Active, not recruiting

Research Question(s):

Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease, affecting over 3 million individuals worldwide and causing progressive lung function deterioration and death within a median of 3-5 years after diagnosis. This project will help to characterize the interstitial lung disease (ILD) patient care continuum across ILD subtypes.